Gazyva, whose active substance is obinutuzumab, is a medicine used to treat chronic lymphocytic leukemia in adults.
This remedy, produced by the laboratory Roche, is composed of Monoclonal Antibodies and should be used in conjunction with Clorambucil, for the treatment of leukemia. Gazyva should be administered intravenously by a healthcare professional for 6 cycles of treatment with 28 days each.
Indications of the Gazyva
Gazyva, in combination with Chlorambucil, is indicated for the treatment of chronic lymphocytic leukemia in adults who have not received another medicine before and who have two or more health problems.
How to use Gazyva
Gazyva should be administered by intravenous infusion by a healthcare professional in 6 treatment cycles of 28 days each. Before each infusion with Gazyva, the patient should take an analgesic / antipyretic, antihistamine and glucocorticoid medication, as directed by the physician.
Side effects of Gazyva
Side effects of Gazyva include infusion-related reactions that are manifested by symptoms such as nausea, chills, falls or elevated blood pressure, fever, vomiting, shortness of breath, redness, headache, rapid heartbeat and diarrhea, number low number of white blood cell types, reduced platelet count, infections, fever at the site of administration, cough, increased uric acid, back pain, joint pain, hair loss and severe allergy.
Contraindications of Gazyva
Gazyva is contraindicated in patients with hypersensitivity to formula components and in children below 18 years of age.
This medicine should not be used during pregnancy and lactation without medical advice.
Learn more about this disease in: Leukemia.
